Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05986864 · ClinicalTrials.gov registry record · Phase 1

Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

A Phase 1 study of Neovascular Age-related Macular Degeneration, sponsored by Skyline Therapeutics (US).

Recruiting
Registry status
Phase 1
Development phase
68
Enrollment target
9
Study locations

NCT05986864: Recruiting Phase 1 study of Neovascular Age-related Macular Degeneration, sponsored by Skyline Therapeutics (US).

NCT05986864 is a Phase 1 study of Neovascular Age-related Macular Degeneration that is actively recruiting participants, run by Skyline Therapeutics (US). The registered enrollment target is 68 participants, below the 407-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (83% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05986864, a Phase 1 study of Neovascular Age-related Macular Degeneration, is actively recruiting participants, sponsored by Skyline Therapeutics (US).

RECRUITING
Registry status
Phase 1
Development phase
68 participants
Enrollment target
9
Study locations

Study Summary

This is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD. Based on results from the phase 1 dose escalation study, the phase 2 expansion study will be conducted.

Conditions Studied

Neovascular Age-related Macular Degeneration

Interventions

  • GENETIC SKG0106

Study Locations (9)

Zhejiang

  • Zhejiang Provincial People's Hospital - Hangzhou
  • Eye Hospital, WMU (Zhejiang Eye Hospital) - Wenzhou

Other

  • Beijing Hospital - Beijing
  • Peking Union Medical College Hospital - Beijing

Florida

  • Retina Vitreous Associates of Florida - Saint Petersburg - St. Petersburg

Massachusetts

  • Ophthalmic Consultants of Boston - Boston

Texas

  • Retina Consultants of Texas - Katy

Virginia

  • Wagner Kapoor Research Institute - Norfolk

Anhui

  • The Second Hospital Of Anhui Medical University - Hefei

Trial Details

FieldValue
Enrollment Target 68 participants
Start Date 2024-02-23
Est. Completion 2026-01-30
Phase Phase 1
Skyline Therapeutics (US)

1 total trials

What NCT05986864 shows while recruiting

NCT05986864 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 407-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (83% lower).

The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which SKG0106 is the first listed.

NCT05986864 lists 9 locations in 7 states (Zhejiang, Other, Florida).

Frequently Asked Questions

What is clinical trial NCT05986864 about?

NCT05986864 is a clinical study titled "Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)". This is a phase 1/2 clinical study to evaluate the safety, preliminary efficacy, immunogenicity, and pharmacokinetic (PK) characteristics of SKG0106 in subjects with nAMD. Based on results from the phase 1 dose escalation study, the phase 2 expansion study will be conducted.

What is the current status of trial NCT05986864?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2024-02-23. Estimated completion is 2026-01-30.

What conditions does trial NCT05986864 study?

This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.

What interventions are being tested in trial NCT05986864?

The interventions under investigation include: SKG0106 (GENETIC).

Who is sponsoring clinical trial NCT05986864?

This trial is sponsored by Skyline Therapeutics (US), which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05986864 being conducted?

This trial has 9 study locations across Florida, Massachusetts, Texas, Virginia, Anhui. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neovascular Age-related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05986864's enrollment target sits among peer trials

68 18th of 33 higher than 16 of 33 other Neovascular Age-related Macular Degeneration trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neovascular Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02044497 · 68 participants · Phase 4

    Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients

  • NCT03779854 · 68 participants · Phase 2

    Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

  • NCT03821246 · 68 participants · Phase 2

    Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

  • NCT04115514 · 68 participants · Phase 2

    Treatment of ARDS With Instilled T3

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05986864

Source: ClinicalTrials.gov NCT05986864, the US trial registry maintained by the National Library of Medicine. NCT05986864 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.